Peregrine Capital Management LLC trimmed its holdings in shares of Evolent Health Inc (NYSE:EVH) by 8.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 870,927 shares of the technology company’s stock after selling 80,489 shares during the period. Peregrine Capital Management LLC owned approximately 1.11% of Evolent Health worth $24,734,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Metropolitan Life Insurance Co. NY boosted its stake in shares of Evolent Health by 12.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 22,031 shares of the technology company’s stock worth $464,000 after buying an additional 2,459 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Evolent Health by 16.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,773 shares of the technology company’s stock worth $458,000 after buying an additional 3,150 shares during the last quarter. Legal & General Group Plc raised its holdings in Evolent Health by 16.8% in the 1st quarter. Legal & General Group Plc now owns 26,437 shares of the technology company’s stock worth $377,000 after purchasing an additional 3,811 shares during the period. NumerixS Investment Technologies Inc bought a new position in Evolent Health in the 2nd quarter worth $105,000. Finally, MetLife Investment Advisors LLC raised its holdings in Evolent Health by 24.8% in the 2nd quarter. MetLife Investment Advisors LLC now owns 31,066 shares of the technology company’s stock worth $654,000 after purchasing an additional 6,178 shares during the period.
In other news, General Counsel Jonathan Weinberg sold 15,000 shares of Evolent Health stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $27.12, for a total value of $406,800.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Thomas Peterson III sold 30,000 shares of Evolent Health stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $25.00, for a total value of $750,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 204,607 shares of company stock worth $5,240,751. Insiders own 4.82% of the company’s stock.
Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Tuesday, November 6th. The technology company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.07. The business had revenue of $150.16 million for the quarter, compared to analysts’ expectations of $142.94 million. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. The business’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period last year, the firm earned ($0.18) earnings per share. Sell-side analysts anticipate that Evolent Health Inc will post -0.37 earnings per share for the current fiscal year.
A number of brokerages recently commented on EVH. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $34.00 target price on shares of Evolent Health in a report on Wednesday. Cowen raised their target price on Evolent Health from $29.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, September 13th. ValuEngine raised Evolent Health from a “hold” rating to a “buy” rating in a report on Thursday, August 9th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $37.00 target price on shares of Evolent Health in a report on Wednesday, September 12th. Finally, Wells Fargo & Co raised their target price on Evolent Health from $26.00 to $34.00 and gave the stock an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. Evolent Health has an average rating of “Buy” and an average price target of $31.73.
ILLEGAL ACTIVITY WARNING: “Evolent Health Inc (NYSE:EVH) Holdings Lessened by Peregrine Capital Management LLC” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/2018/11/10/peregrine-capital-management-llc-sells-80489-shares-of-evolent-health-inc-evh/2846783.html.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Further Reading: How dollar cost averaging works
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.